Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text
The company concluded that its shot was superior to GSK’s product.
Simplified Text
Moderna concluded its flu shot was superior to GSK’s product
Confidence Score
0.900
Claim Maker
The author
Context Type
News Article
Context Details
{
    "vaccine": "flu shot",
    "organization": "Moderna",
    "comparison_product": "GSK's product"
}
Subject Tags
Health
UUID
a1164c03-b055-4c6a-97d5-87e39d435469
Vector Index
✗ No vector
Created
February 15, 2026 at 4:02 PM (2 months ago)
Last Updated
February 15, 2026 at 4:02 PM (2 months ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html
F.D.A. Rejects Moderna’s M.R.N.A. Flu Vaccine, a Sign of Policy Shift
Completed News
30 claims 🔥
2 months ago
https://nytimes.com/2026/02/10/health/fda-moderna-mrna-flu-vaccine.html

The FDA rejected Moderna's mRNA flu vaccine, signaling a shift in federal health policy under Health Secretary Robert F. Kennedy Jr. The rejection is based on concerns about the clinical trial's comparison product. Moderna's stock has plummeted since its peak.

FDA Moderna mRNA Vaccine Flu Vaccine Robert F. Kennedy Jr. Vaccine Policy Vaccine Development

Similar Claims (0)

Other claims identified as semantically similar to this one.

No similar claims found

This claim appears to be unique in the system.